Detalles de la búsqueda
1.
Incidence and survival of primary metastatic breast cancer in Denmark; implication of breast cancer screening, classification, and staging practice.
Acta Oncol
; 63: 277-287, 2024 May 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-38711384
2.
High inter-laboratory variability in the assessment of HER2-low breast cancer: a national registry study on 50,714 Danish patients.
Breast Cancer Res
; 25(1): 139, 2023 11 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-37946261
3.
Adjuvant chemotherapy in patients with ER-negative/HER2-negative, T1abN0 breast cancer: a nationwide study.
Breast Cancer Res Treat
; 198(1): 103-112, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36576678
4.
Identifying recurrent breast cancer patients in national health registries using machine learning.
Acta Oncol
; 62(4): 350-357, 2023 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-37074036
5.
Evaluation of tumor-infiltrating lymphocytes, PD-L1, and PIK3CA mutations and association with prognosis in HER2-positive early stage breast cancer.
Acta Oncol
; 62(12): 1913-1920, 2023 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-37961947
6.
Real-world survival of Danish patients with HER2-positive metastatic breast cancer.
Acta Oncol
; 62(6): 601-607, 2023 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-37338513
7.
A retrospective, non-interventional study of breast cancer patients diagnosed with ER+/HER2 negative, locally advanced or metastatic breast cancer treated with palbociclib in Denmark.
Acta Oncol
; 62(3): 290-297, 2023 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-37010239
8.
A nationwide observational study in heavily pretreated metastatic HER2-positive breast cancer patients.
Acta Oncol
; 62(2): 126-133, 2023 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-36929759
9.
Benefit of adjuvant chemotherapy and trastuzumab in patients with HER2-positive, node-negative breast tumors ≤ 10 mm: a nationwide study.
Breast Cancer Res Treat
; 196(1): 197-206, 2022 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-36076126
10.
Interventions supporting cancer patients in making decisions regarding participation in clinical trials - a systematic review.
BMC Cancer
; 22(1): 1097, 2022 Oct 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-36289456
11.
Tumour-infiltrating lymphocytes and response to neoadjuvant letrozole in patients with early oestrogen receptor-positive breast cancer: analysis from a nationwide phase II DBCG trial.
Breast Cancer Res
; 22(1): 46, 2020 05 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32410705
12.
Induction of PIK3CA alterations during neoadjuvant letrozole may improve outcome in postmenopausal breast cancer patients.
Breast Cancer Res Treat
; 184(1): 123-133, 2020 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-32748297
13.
Synchronous bilateral breast cancer: a nationwide study on histopathology and etiology.
Breast Cancer Res Treat
; 182(1): 229-238, 2020 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-32441019
14.
Breast cancer mortality in synchronous bilateral breast cancer patients.
Br J Cancer
; 120(7): 761-767, 2019 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-30804429
15.
Routine surveillance for symptomatic toxicities with real-time clinician reporting in Danish breast cancer patients-Organization and design of the first national, cluster randomized trial using the Patient-Reported Outcomes version of Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Breast J
; 25(2): 269-272, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30761667
16.
Predicting efficacy of epirubicin by a multigene assay in advanced breast cancer within a Danish Breast Cancer Cooperative Group (DBCG) cohort: a retrospective-prospective blinded study.
Breast Cancer Res Treat
; 172(2): 391-400, 2018 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-30099635
17.
Forty years of landmark trials undertaken by the Danish Breast Cancer Cooperative Group (DBCG) nationwide or in international collaboration.
Acta Oncol
; 57(1): 3-12, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29205077
18.
Mortality and recurrence rates among systemically untreated high risk breast cancer patients included in the DBCG 77 trials.
Acta Oncol
; 57(1): 135-140, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29168407
19.
Molecular subtyping of breast cancer improves identification of both high and low risk patients.
Acta Oncol
; 57(1): 58-66, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29164972
20.
Neoadjuvant letrozole for postmenopausal estrogen receptor-positive, HER2-negative breast cancer patients, a study from the Danish Breast Cancer Cooperative Group (DBCG).
Acta Oncol
; 57(1): 31-37, 2018 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-29168427